» Articles » PMID: 36243801

ENPP1 Deletion Causes Mouse Osteoporosis Via the MKK3/p38 MAPK/PCNA Signaling Pathway

Overview
Publisher Biomed Central
Specialty Orthopedics
Date 2022 Oct 15
PMID 36243801
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Apart from the current understanding of enzyme function, the mechanism of ectonucleotide pyrophosphatase/phosphodiesterase 1 (Enpp1) deficiency-associated osteoporosis is unknown. We aimed to explore the changes in the expression of signaling pathways of bone tissues involved in Enpp1 deficiency.

Methods: The body weights and morphology and histology of the bones of male Enpp1 knockout (KO) and wild-type (WT) mice were assessed. The humeri of WT and Enpp1 KO mice at 12 weeks of age were subjected to high-throughput quantitative molecular measurements, and bioinformatics analysis was performed. Proteins from humeri and calvarial pre-osteoblasts (Pobs) were used to verify the differentially expressed signaling pathways and to explain the mechanism of Enpp1 deficiency-associated osteoporosis.

Results: Enpp1 KO mice had significantly lower body weight and trabecular bone mass in the hindlimbs than WT mice. Proteomics and immunoblotting showed that Enpp1 deletion downregulated the expression of the p38 mitogen-activated protein kinase (MAPK) signaling pathway in bones. Lysophosphatidic acid (LPA) was involved in activating the MKK3/p38 MAPK/PCNA pathway and proliferating Pobs in Enpp1 KO mice, whereas a p38 MAPK inhibitor suppressed the LPA-induced pro-proliferation phenotype (p < 0.05).

Conclusion: The inhibition of MKK3/p38 MAPK/PCNA pathway plays an important role in the development of osteoporosis caused by Enpp1 deficiency, and LPA partially rescued the proliferation of pre-osteoblasts via the MKK3/p38 MAPK/PCNA pathway.

Citing Articles

Unveiling the therapeutic promise: exploring Lysophosphatidic Acid (LPA) signaling in malignant bone tumors for novel cancer treatments.

Qi Y, Wang Y, Yuan J, Xu Y, Pan H Lipids Health Dis. 2024; 23(1):204.

PMID: 38943207 PMC: 11212261. DOI: 10.1186/s12944-024-02196-9.


Enpp1 deficiency caused chondrocyte apoptosis by inhibiting AMPK signaling pathway.

Gao Z, Wang Q, Guo K, Li X, Huang Y J Orthop Surg Res. 2023; 18(1):462.

PMID: 37370114 PMC: 10294376. DOI: 10.1186/s13018-023-03923-1.

References
1.
Okawa A, Nakamura I, Goto S, Moriya H, Nakamura Y, Ikegawa S . Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine. Nat Genet. 1998; 19(3):271-3. DOI: 10.1038/956. View

2.
Willemsen M, Krebbers G, Bekkenk M, Teunissen M, Luiten R . Improvement of Opal Multiplex Immunofluorescence Workflow for Human Tissue Sections. J Histochem Cytochem. 2021; 69(5):339-346. PMC: 8091416. DOI: 10.1369/00221554211007793. View

3.
Xie B, Zeng Z, Liao S, Zhou C, Wu L, Xu D . Kaempferol Ameliorates the Inhibitory Activity of Dexamethasone in the Osteogenesis of MC3T3-E1 Cells by JNK and p38-MAPK Pathways. Front Pharmacol. 2021; 12:739326. PMC: 8524096. DOI: 10.3389/fphar.2021.739326. View

4.
Greenblatt M, Shim J, Zou W, Sitara D, Schweitzer M, Hu D . The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in mice. J Clin Invest. 2010; 120(7):2457-73. PMC: 2898605. DOI: 10.1172/JCI42285. View

5.
Yu Z, Li D, Huang X, Xing X, Yu R, Li Z . Lysophosphatidic acid upregulates connective tissue growth factor expression in osteoblasts through the GPCR/PKC and PKA pathways. Int J Mol Med. 2016; 37(2):468-74. DOI: 10.3892/ijmm.2016.2450. View